 Home > Active Ingredient News > Antitumor Therapy > How to choose the second-line treatment for advanced NSCLC immunotherapy combined with chemotherapy (IO-CT) resistance?

How to choose the second-line treatment for advanced NSCLC immunotherapy combined with chemotherapy (IO-CT) resistance?

 Last Update: 2022-08-19
 Source: Internet
 Author: User

Tags

double 3 4

polychondritis treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The IO-CT combination has become the standard of care for patients with aNSCLC with low or moderate programmed death ligand 1 (PD-L1) expression (<50%) and is also an option for patients with high PDL1 expression (≥50%.

This study was a retrospective international study including patients who progressed under a first-line IO-CT regime.

This study enrolled 125 patient.

In the IO-CT major resistant population (n=21), mOS-L2 was not achieved in the platinum-containing chemotherapy group, compared with 8, 2, and 7 months in the T-mono, T-AA, and other chemotherapy groups, respectivel.

The results show that for aNSCLC patients, second-line therapy after IO-CT can provide a certain curative effec.

Original source:

OA006-Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.